Soluble CD137 and risk of hepatocellular carcinoma: nested case–control studies in cohorts in Shanghai and Singapore
Menée à partir d'échantillons sériques prélevés avant diagnostic sur 512 patients atteints d'un carcinome hépatocellulaire et sur 512 témoins, cette étude met en évidence une association entre le niveau sérique du CD137 soluble et le risque de développer la maladie
Background : The majority of hepatocellular carcinoma (HCC) cases occur in the presence of cirrhosis. Biomarkers of cirrhosis-associated immune dysfunction such as CD8+ T cell cytokines could aid HCC risk assessment.
Methods : CD8+ T cell cytokines were determined in pre-diagnostic serum in two studies including 315 HCC case–control pairs in the Shanghai Cohort Study (SCS) and 197 pairs in the Singapore Chinese Health Study (SCHS). Conditional logistic regression was used to estimate odds ratio (OR) and 95% confidence interval (CI) for HCC with levels of five cytokines—soluble CD137 (sCD137), soluble Fas (sFas), perforin, macrophage inflammatory protein 1-beta (MIP-1
β), and tumour necrosis factor alpha (TNF-α).
Results
:
sCD137 levels were significantly higher in HCC cases than controls in both cohorts (Ps
< 0.001). Compared with the lowest quartile, multivariable-adjusted ORs (95% CI) of HCC for the highest sCD137 quartile were 3.79 (1.73, 8.30) in the SCS and 3.49 (1.44, 8.48) in the SCHS. The sCD137-HCC association was independent of hepatitis B seropositivity and follow-up time. No other cytokine was consistently associated with HCC risk.
Conclusion : sCD137 was associated with higher risk of HCC in two studies nested in general population cohorts. sCD137 may be a long-term risk marker of HCC development.
British Journal of Cancer , résumé, 2023